|
US3132171A
(en)
|
1962-06-18 |
1964-05-05 |
Strong Cobb Arner Inc |
3, 4-diphosphatophenyl-alanine and process for making same
|
|
IL58849A
(en)
|
1978-12-11 |
1983-03-31 |
Merck & Co Inc |
Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
|
|
US4543256A
(en)
|
1982-03-17 |
1985-09-24 |
Northeastern University |
(-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
|
|
DE19575006I2
(de)
|
1981-10-16 |
2003-01-09 |
Novartis Ag |
1, 2, 3, 4a, 5, 10, 10a-Octahydrobenzo(g)chinolin-Derivate mit pharmazeutischer Wirkung
|
|
FR2540112B1
(fr)
|
1983-02-01 |
1986-08-29 |
Sandoz Sa |
Nouveaux derives de la benzo(g)quinoleine, leur preparation et leur utilisation comme medicaments
|
|
JPS60172975A
(ja)
|
1984-02-15 |
1985-09-06 |
Sumitomo Chem Co Ltd |
エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
|
|
GB2192394A
(en)
|
1986-07-11 |
1988-01-13 |
Glaxo Group Ltd |
Amine derivatives
|
|
IT1226727B
(it)
|
1988-07-29 |
1991-02-05 |
Simes |
Farmaci precursori della dopamina.
|
|
ES2070994T3
(es)
|
1989-04-20 |
1995-06-16 |
Zambon Spa |
Profarmaco de dopamina.
|
|
WO1990012574A1
(en)
|
1989-04-25 |
1990-11-01 |
Northeastern University |
Dopamine agonist compounds
|
|
IT1271411B
(it)
|
1993-09-14 |
1997-05-28 |
Zambon Spa |
Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
|
|
US5955468A
(en)
|
1993-12-21 |
1999-09-21 |
Sandoz Ltd. |
Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
|
|
TW357143B
(en)
|
1995-07-07 |
1999-05-01 |
Novartis Ag |
Benzo[g]quinoline derivatives
|
|
IT1289979B1
(it)
|
1997-02-26 |
1998-10-19 |
Zambon Spa |
5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
|
|
US6410664B1
(en)
|
1997-03-24 |
2002-06-25 |
Cryovac, Inc. |
Catalyst compositions and processes for olefin polymers and copolymers
|
|
GB9902938D0
(en)
|
1999-02-10 |
1999-03-31 |
Novartis Ag |
Organic compounds
|
|
CO5261532A1
(es)
|
1999-11-15 |
2003-03-31 |
Novartis Ag |
Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
|
|
MXPA02009904A
(es)
|
2000-04-07 |
2004-09-06 |
Tap Pharmaceutical Prod Inc |
Derivados de apomorfina y metodos para su uso.
|
|
SE0001438D0
(sv)
|
2000-04-18 |
2000-04-18 |
Axon Chemicals Bv |
New chemical compounds and their use in therapy
|
|
KR20030027020A
(ko)
|
2000-08-11 |
2003-04-03 |
펄듀 리서치 파운데이션 |
디나프솔린의 제조 공정
|
|
SE0102036D0
(sv)
|
2001-06-08 |
2001-06-08 |
Axon Biochemicals Bv |
Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
|
|
SE0002934D0
(sv)
|
2000-08-17 |
2000-08-17 |
Axon Biochemicals Bv |
New aporphine esters and in their use in therapy
|
|
PE20030240A1
(es)
|
2001-07-09 |
2003-04-16 |
Novartis Ag |
DERIVADOS DE BENZO [g] QUINOLINA
|
|
DE60220800D1
(de)
|
2001-08-10 |
2007-08-02 |
Purdue Research Foundation |
Chirales dinapsolin
|
|
EG24415A
(en)
|
2002-03-07 |
2009-05-25 |
Novartis Ag |
Quinoline derivatives
|
|
CA2479372A1
(en)
|
2002-03-19 |
2003-10-02 |
Michael Holick |
Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
|
|
US7101912B2
(en)
|
2002-12-06 |
2006-09-05 |
Xenoport, Inc. |
Carbidopa prodrugs and derivatives, and compositions and uses thereof
|
|
US20070155720A1
(en)
|
2003-12-23 |
2007-07-05 |
Darpharma, Inc. |
Co-administration of dopamine-receptor binding compounds
|
|
US7648995B2
(en)
|
2004-04-13 |
2010-01-19 |
The Mclean Hospital Corporation |
R(—)-11-hydroxyaporphine derivatives and uses thereof
|
|
WO2006012640A2
(en)
|
2004-07-21 |
2006-02-02 |
Darpharma, Inc. |
Method of administration of dopamine receptor agonists
|
|
WO2006056604A1
(en)
|
2004-11-25 |
2006-06-01 |
Evolva Ag |
Levodopa glycosyl derivatives, methods of preparation and use
|
|
US20090124651A1
(en)
|
2007-08-31 |
2009-05-14 |
H. Lundbeck A/S |
Catecholamine derivatives and prodrugs thereof
|
|
TWI404702B
(zh)
|
2007-08-31 |
2013-08-11 |
Lundbeck & Co As H |
兒茶酚胺衍生物和其前藥
|
|
CN102131790A
(zh)
|
2008-06-27 |
2011-07-20 |
H.隆德贝克有限公司 |
新型苯酚型和儿茶酚型胺及其前药
|
|
TW201036949A
(en)
|
2009-02-27 |
2010-10-16 |
Lundbeck & Co As H |
Treatment of dyskinesia related disorders
|
|
TW201035054A
(en)
|
2009-02-27 |
2010-10-01 |
Lundbeck & Co As H |
Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
|
|
EP2557079A1
(en)
|
2011-08-09 |
2013-02-13 |
Nestec S.A. |
Synthesis of catechin and epicatechin conjugates
|
|
DE102011112496A1
(de)
|
2011-09-07 |
2013-03-07 |
Thanares GmbH |
4-Methylcatecholderivate und deren Verwendung
|
|
CN102746351B
(zh)
|
2012-07-23 |
2018-03-02 |
上海弈柯莱生物医药科技有限公司 |
灯盏花乙素及其类似物的制备方法
|
|
GB201319768D0
(en)
|
2013-11-08 |
2013-12-25 |
Glycosynth Ltd |
Naphthalene derived chromogenic enzyme substrates
|
|
RU2021103000A
(ru)
|
2014-10-21 |
2021-03-01 |
Эббви Инк. |
Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
|
|
CN105218606B
(zh)
|
2015-10-19 |
2017-12-01 |
昆明理工大学 |
一种制备灯盏乙素的方法
|
|
EP4295909A3
(en)
|
2016-04-20 |
2024-07-17 |
AbbVie Inc. |
Carbidopa and l-dopa prodrugs and methods of use
|
|
US9920342B2
(en)
|
2016-05-17 |
2018-03-20 |
Divi's Laboratories Limited |
Process for the preparation of Droxidopa
|
|
CR20200225A
(es)
|
2017-11-24 |
2020-07-25 |
H Lundbeck As |
Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
|
|
US11104697B2
(en)
|
2019-05-20 |
2021-08-31 |
H. Lundbeck A/S |
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
|
|
US11130775B2
(en)
|
2019-05-20 |
2021-09-28 |
H. Lundbeck A/S |
Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
|
|
US11111263B2
(en)
|
2019-05-20 |
2021-09-07 |
H. Lundbeck A/S |
Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
|
|
US11168056B2
(en)
|
2019-05-20 |
2021-11-09 |
H. Lundbeck A/S |
Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
|
|
WO2020234276A1
(en)
|
2019-05-21 |
2020-11-26 |
H. Lundbeck A/S |
New catecholamine prodrugs for use in the treatment of parkinson's disease
|
|
EP3972971A1
(en)
|
2019-05-21 |
2022-03-30 |
H. Lundbeck A/S |
New catecholamine prodrugs for use in the treatment of parkinson's diseases
|
|
WO2020234277A1
(en)
|
2019-05-21 |
2020-11-26 |
H. Lundbeck A/S |
Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
|
|
EP4247793A1
(en)
|
2020-11-17 |
2023-09-27 |
H. Lundbeck A/S |
New catecholamine prodrugs for use in the treatment of parkinson's disease
|